UroGen Pharma (URGN) to Release Earnings on Thursday

UroGen Pharma (NASDAQ:URGN) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

UroGen Pharma Trading Up 5.9 %

Shares of NASDAQ URGN opened at $10.17 on Thursday. UroGen Pharma has a 1 year low of $9.03 and a 1 year high of $20.70. The stock has a market cap of $238.53 million, a P/E ratio of -3.23 and a beta of 1.08. The firm has a 50-day moving average of $10.49 and a 200 day moving average of $11.85. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $64.00 target price on shares of UroGen Pharma in a research report on Tuesday, February 25th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a report on Tuesday, February 18th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, UroGen Pharma presently has an average rating of “Buy” and a consensus price target of $40.00.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.